🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Vaccinex is pioneering a differentiated approach to treating cancer and neurologic diseases through the inhibition of semaphorin 4D (SEMA4D). Learn more about our work here: bit.ly/3nN9ltS $VCNX

Vaccinex is pleased to attend the PEGS Summit Summit taking place May 12-16. During the conference Ernest Smith, PhD will present a poster on May 13 and 14. For more information about the conference, visit: bit.ly/38oC0nf $VCNX #PEGSummit

Attending PEGS Summit Summit? Learn how Vaccinex's ActivMAb technology can help your company move faster from the bench to the clinic during our poster presentation on Tuesday, May 13 & Wednesday, May 14. bit.ly/38oC0nf #PEGSummit

Vaccinex is pleased to announce a collaboration with Single Cell Technology and AbTherx who will incorporate Vaccinex’s ActivMAb® Technology into their respective workflows for complex drug targets. For more info, visit: bit.ly/3Sx9jbh $VCNX

Vaccinex's Ernest Smith comments on the Company's collaboration with Single Cell Technology and AbTherx to tackle challenging antibody drug targets. Learn more: bit.ly/3Sx9jbh $VCNX

AbTherx and Single Cell Technology will incorporate Vaccinex's ActivMAb® Technology into Atlas™ Mouse and AbTheneum™ antibody discovery platforms. Learn more about our new collaboration here: bit.ly/3Sx9jbh $VCNX

Need GLP1-R antigen virions for your next project? Maximize your chances for success against difficult protein targets with Vaccinex's ActivMab® antigen virions! Learn more here: bit.ly/3rvfRNP $VCNX

In Huntington’s & #Alzheimers, SEMA4D triggers neuroinflammation with an associated loss of brain functions that accelerates disease progression. Pepinemab is being developed to block SEMA4D to potentially preserve functions and slow or prevent progression bit.ly/3ZuW5gU

Vaccinex collaborators Emory University recently presented new data at #ASCO25 characterizing the unique mechanism of pepinemab to enhance immune responses to checkpoint therapies that are associated with improved clinical response in patients with #HNSCC. $VCNX

Vaccinex is leveraging its proprietary drug discovery platform, ActivMAb®, to create opportunities for future pipeline expansion and strategic collaborations. Learn more our proprietary mammalian based antibody discovery platform here: bit.ly/2WtsTsg $VCNX

New data presented at #ASCO25 showed neoadjuvant treatment with pepinemab appeared to significantly increase density of mature tertiary lymphoid structures (TLS), a biomarker associated with long-term clinical benefit that correlates with improved clinical benefit $VCNX #HNSCC

Vaccinex's Biosafety Level 1 antigen virions efficiently incorporate multi-pass proteins into their outer membrane and are easily isolated from the culture medium. Learn more about our antigen virions and view our full catalog here: bit.ly/3rvfRNP $VCNX

Pepinemab has potential to be a major advancement for #HNSCC patients with cold & resistant disease. Learn about pepinemab's potential to turn immunologically cold tumors, such as HPV-negative head and neck cancer, into hot immune centers by inducing robust & mature TLS. $VCNX

Vaccinex’s lead clinical programs are focused on inhibition of SEMA4D, a novel target and an important biological effector whose expression is implicated in the progression of a number of neurological diseases and cancers. See our pipeline here: bit.ly/2O4G4yP $VCNX

Vaccinex is pioneering a differentiated approach to treating #AlzheimersDisease through the inhibition of semaphorin 4D (SEMA4D). Learn more about our work to provide new hope to those affected by #Alzheimers here: bit.ly/3nN9ltS $VCNX

Pepinemab is a humanized monoclonal IgG4 antibody that binds & blocks the signaling activity of SEMA4D, an extracellular signaling molecule that regulates the migration and activation of immune and inflammatory cells at sites of injury and #cancer. bit.ly/3nN9ltS $VCNX

Pepinemab, in combination with a checkpoint inhibitor, has been found to significantly enhance immune cell communication & to simultaneously reduce immunosuppressive mechanisms in tumors, a potentially powerful combination to increase anti-tumor activity. bit.ly/3fA7hEn

ActivMab® offers two antigenically distinct poxviruses compatible w/ in vivo & in vitro antibody discovery methods to maximize specificity for the target antigen. See how we can help maximize your chances for success against difficult protein targets bit.ly/3rvfRNP $VCNX

As the world’s population ages, there is an urgent need for new therapeutic options to address diseases such as #Alzheimers & dementia. Learn how Vaccinex is developing pepinemab to help provide new treatment options for those affected by AD bit.ly/37B7S3E $VCNX

Evidence suggests SEMA4D expression is correlated w/ tumor aggression in cancer patients & appears to block immune cell activity in tumors. Vaccinex is developing pepinemab, a monoclonal antibody targeting SEMA4D, in combo w/ pembrolizumab for HNSCC. bit.ly/3fA7hEn $VCNX